Overview

Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of glioblastoma multiforme. Phase II trial to study the effectiveness of gefitinib in treating patients who have newly diagnosed glioblastoma multiforme.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Gefitinib